Kancera AB Valuation
| KAN Stock | SEK 1.45 0.04 2.68% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Kancera AB secures a last-minute Real Value of kr1.24 per share. The latest price of the firm is kr1.45. Our model forecasts the value of Kancera AB from analyzing the firm fundamentals such as Operating Margin of (72.39) %, return on equity of -0.47, and Shares Outstanding of 79.53 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Kancera AB's price fluctuation is extremely dangerous at this time. Calculation of the real value of Kancera AB is based on 3 months time horizon. Increasing Kancera AB's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Kancera AB's intrinsic value may or may not be the same as its current market price of 1.45, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.45 | Real 1.24 | Hype 1.45 | Naive 1.36 |
The intrinsic value of Kancera AB's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Kancera AB's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Kancera AB helps investors to forecast how Kancera stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Kancera AB more accurately as focusing exclusively on Kancera AB's fundamentals will not take into account other important factors: Kancera AB Total Value Analysis
Kancera AB is now estimated to have takeover price of 14.76 M with market capitalization of 262.69 M, debt of 442 K, and cash on hands of 106.52 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Kancera AB fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
14.76 M | 262.69 M | 442 K | 106.52 M |
Kancera AB Investor Information
About 14.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.44. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Kancera AB recorded a loss per share of 0.87. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 24th of February 2021. Based on the measurements of operating efficiency obtained from Kancera AB's historical financial statements, Kancera AB is not in a good financial situation at the moment. It has a very high risk of going through financial straits in August.Kancera AB Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Kancera AB has an asset utilization ratio of 1.28 percent. This implies that the Company is making kr0.0128 for each dollar of assets. An increasing asset utilization means that Kancera AB is more efficient with each dollar of assets it utilizes for everyday operations.Kancera AB Ownership Allocation
Kancera AB maintains a total of 79.53 Million outstanding shares. Kancera AB secures 13.72 % of its outstanding shares held by insiders and 2.86 % owned by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Kancera AB Profitability Analysis
The company reported the revenue of 1.7 M. Net Loss for the year was (45.69 M) with profit before overhead, payroll, taxes, and interest of 1.7 M.About Kancera AB Valuation
The stock valuation mechanism determines Kancera AB's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Kancera AB based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Kancera AB. We calculate exposure to Kancera AB's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Kancera AB's related companies.Kancera AB , a biotechnology company, engages in the development and sale of drug candidates to pharmaceutical companies in Sweden and internationally. The company was founded in 2010 and is based in Solna, Sweden. Kancera AB operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange.
8 Steps to conduct Kancera AB's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Kancera AB's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Kancera AB's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Kancera AB's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Kancera AB's revenue streams: Identify Kancera AB's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Kancera AB's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Kancera AB's growth potential: Evaluate Kancera AB's management, business model, and growth potential.
- Determine Kancera AB's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Kancera AB's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Kancera Stock Analysis
When running Kancera AB's price analysis, check to measure Kancera AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kancera AB is operating at the current time. Most of Kancera AB's value examination focuses on studying past and present price action to predict the probability of Kancera AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kancera AB's price. Additionally, you may evaluate how the addition of Kancera AB to your portfolios can decrease your overall portfolio volatility.